Skip to content

Advertisement

You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Genomics

Open Access

Initial characterization of drug resistant cancer stem cells isolated from primary brain tumors (astrocytoma) cell lines generated from Saudi patients

  • Ishaq Khan1Email author,
  • Mohammed Bangash3,
  • Saleh S Baeesa3,
  • Awatif Jamal3,
  • Hanadi Qashqari2,
  • Adel Abuzenadah1,
  • Mohammed H. AlQahtani1,
  • Ghazi Damanhouri2,
  • Hans-Juergen Schulten1,
  • Deema Hussein2 and
  • Adeel Chaudhary1
BMC Genomics201415(Suppl 2):P53

https://doi.org/10.1186/1471-2164-15-S2-P53

Published: 2 April 2014

Background

The Cancer Stem Cells (CSCs) hypothesis proposes that malignant brain tumours are organized into aberrant cell hierarchies where a subset of parent CSCs replicate asymmetrically and unlimitedly to produce differentiated daughter cell [1, 2]. These parent CSCs are highly adaptive and resistant to the chemotherapeutic drugs [3]. Developing new drugs that target CSCs requires a comprehensive understanding of the pharmacogenomics behavior of these cells [4, 5]. Such understanding requires reliable in vitro and in vivo models that represent the beneficial patients. This project is set out to: i) Establish a collection of astrocytoma cell lines generated from Saudi patients, ii) Select drug resistant brain tumour CSCs, iii) Characterize drug resistant brain tumour CSCs individually, and iv) Deduce common features for drug resistant brain tumour CSCs.

Materials and methods

A range of methodologies will be applied including, tumour cell line derivation methods, the clonogenic selection assay, cytogenetics profiles, neuronal cancer stem cells characterisation assays and in vivo tumourgenic assays.

Results

Optimisation of methods used to establish astrocytoma cell lines generated from Saudi patients was completed. To date two novel primary astrocytoma cell lines have been derived. Full clinical data related to the cell lines was retrieved. Currently, optimisation of the clonogenic selection assay and immunostaining for cancer stem cells markers are under progress.

Conclusions

Successful retrieval of primary astrocytoma cell lines was possible to accomplish. Important clinical information data relevant to the cell lines were obtained providing clear identification reference. Further work is required for the characterization of the drug resistant cancer stem cell component within these cell lines. Once completed, this research will assist in understanding some of the molecular mechanisms relevant to drug resistance, especially for patients in the Kingdom of Saudi Arabia.

Authors’ Affiliations

(1)
Center of Excellence in Genomic Medicine Research, King Abdulaziz University
(2)
King Fahd Medical Research Centre, King Abdulaziz University
(3)
Medical College, King Abdulaziz University

References

  1. Dirks PB: Brain tumour stem cells: the undercurrents of human brain cancer and their relationship to neural stem cells. Philosophical Transactions of the Royal Society B: Biological Sciences. 2008, 363 (1489): 139-152.View ArticleGoogle Scholar
  2. Khoshnevisan A: An overview of therapeutic approaches to brain tumor stem cells. Medical journal of the Islamic Republic of Iran. 2012, 26 (1): 31-PubMed CentralPubMedGoogle Scholar
  3. Quezada C, Garrido W, Oyarzún C, Fernández K, et al: 5′ ectonucleotidase mediates multipledrug resistance in glioblastoma multiforme cells. Journal of cellular physiology. 2013, 228 (3): 602-608.View ArticlePubMedGoogle Scholar
  4. Maugeri-Saccà M, Vigneri P, De Maria R: Cancer stem cells and chemosensitivity. Clinical Cancer Research. 2011, 17 (15): 4942-4947.View ArticlePubMedGoogle Scholar
  5. Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 2001, 414 (6859): 105-111.View ArticlePubMedGoogle Scholar

Copyright

© Khan et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement